Clinical Trials
26 trialsA Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer
Fudan University
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
The First Affiliated Hospital of Soochow University
NITDC
Peking Union Medical College Hospital
Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma
Sichuan University
Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC
The First Hospital of Hebei Medical University
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
Sun Yat-sen University
TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma
Zhongda Hospital
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
NACSOC-02
Beijing Chao Yang Hospital
DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer
Xijing Hospital
Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma
First Affiliated Hospital Xi'an Jiaotong University
A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）
Harbin Medical University
NSCLC
Henan Provincial People's Hospital
Camrelizumab Utilization on Patients With Advanced Liver Cancer
First Affiliated Hospital Xi'an Jiaotong University
iPLENTY-pvtt
RenJi Hospital
Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer
Henan Cancer Hospital
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
The Central Hospital of Lishui City
Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer
The First Affiliated Hospital of Zhengzhou University
A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC
Beijing Chest Hospital
HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis
Zhejiang Cancer Hospital
Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer
Qianfoshan Hospital
Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC
Tianjin Medical University Cancer Institute and Hospital
PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer
Fujian Cancer Hospital
A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection
Cancer Hospital of Guangxi Medical University
Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC
Tianjin Medical University Cancer Institute and Hospital
SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery
Shanghai Zhongshan Hospital